Magellan Rx Management, the pharmacy benefit management (PBM) division of Magellan Health, Inc., released new data recently showcasing results from its medical pharmacy program focused on biosimilar management.
New data from CPhI shows that, despite ongoing reputational challenges, India’s biologics market is set for robust growth in 2019 driven by biosimilars production.
According to the market research report published by P&S Intelligence, biosimilars market is expected to generate $26.7 billion revenue by 2024, advancing at a CAGR of 29.6% during the forecast period. The market is majorly driven by rising prevalence of chronic diseases, increasing investment in research and development (R&D) activities by biopharmaceutical companies, extensive pipeline of biosimilars, growing geriatric population, and inexpensive nature of biosimilars as compared to reference drugs.
Biosimilar is a type of biological product that is almost identical to the original product, which has undergone patent expiration. Development and validation of biosimilars are an important part of the overall production process.
Teva Canada Innovation, G.P.-.S.E.N.C. announces that Health Canada has granted a notice of compliance (NOC)1 for TRUXIMA™ (rituximab), the first biosimilar to RITUXAN®2 (rituximab) in Canada for the treatment of adult patients in: Non-Hodgkin's Lymphoma (NHL), Chronic Lymphocytic Leukemia (CLL) and Rheumatoid Arthritis (RA).
The Pharmaceutical Care Management Association (PCMA) applauds the Energy and Commerce Subcommittee on Oversight and Investigations for holding today's hearing on the important issue of rising insulin prices.
Selexis SA and Generium JSC recently announced that a fifth Selexis SUREtechnology Platform-generated biological product has been approved for marketing.
The Association for Accessible Medicines welcomes recently’s unanimous 51-0 passage of the CREATES Act by the House Energy and Commerce Committee.
Fresenius Kabi, a global healthcare company that specializes in lifesaving medicines and technologies, announced recently that the European Commission (EC) granted marketing authorization for IDACIO, an adalimumab biosimilar, for all indications of the reference medicine.
Sandoz, a Novartis division and a global leader in biosimilars, today announced resubmission of its Biologics License Application (BLA) for a proposed biosimilar pegfilgrastim to the US Food and Drug Administration (FDA) to address an FDA complete response letter received in June 2016.
|
|
|
|
|
|
|
|
|